Fig. 7From: The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potentialDesign of the PROMINENT study with pemafibrate. Adapted from Pradhan et al. [144] with permission. BID, twice daily; HDL, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; TG, triglyceridesBack to article page